Association of angiotensin‑converting enzyme gene I/D and CYP11B2 gene -344T/C polymorphisms with lone atrial fibrillation and its recurrence after catheter ablation

Zhang,Xian-Ling; Wu,Li-Qun; Liu,Xu; Yang,Yi-Qing; Tan,Hong-Wei; Wang,Xin-Hua; Zhou,Li; Jiang,Wei-Feng; Li,Zheng

doi:10.3892/etm.2012.650

Association of angiotensin‑converting enzyme gene I/D and CYP11B2 gene -344T/C polymorphisms with lone atrial fibrillation and its recurrence after catheter ablation

Authors:
- Xian-Ling Zhang
- Li-Qun Wu
- Xu Liu
- Yi-Qing Yang
- Hong-Wei Tan
- Xin-Hua Wang
- Li Zhou
- Wei-Feng Jiang
- Zheng Li
View Affiliations

Affiliations: Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China , Department of Cardiology, Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China, Department of Cardiovascular Research, Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China
Published online on: July 31, 2012 https://doi.org/10.3892/etm.2012.650
Pages: 741-747

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The renin-angiotensin-aldosterone system (RAAS) plays a key role in atrial structural and electrical remodeling. The aim of this study was to investigate the potential associations of angiotensin‑converting enzyme (ACE) gene insertion/deletion (I/D) and aldosterone synthase (CYP11B2) gene -344T/C polymorphisms with the risk and recurrence of lone atrial fibrillation (AF). One hundred and ninety-three patients who underwent successful catheter ablation for lone AF were recruited. Two hundred and ninety-seven sinus rhythm subjects without a history of arrhythmia served as controls. The subjects were genotyped for ACE gene I/D and CYP11B2 gene -344T/C polymorphisms. Results showed that the ACE gene DD genotype and D allele were associated with a greater prevalence of lone AF (both P<0.01). In addition, the ACE gene DD genotype had a significantly larger left atrial dimension (LAD; 41.6±5.7 mm vs. 39.6±5.2 mm; P=0.043) and higher risk of AF recurrence [44.7% vs. 23.2%; odds ratio (OR), 2.68; 95% confidence interval (CI), 1.28-5.61; P=0.008] compared with the II+ID genotype in lone AF patients. After adjustment for a variety of risk factors, the ACE gene DD genotype had a 1.97‑fold increased risk for lone AF (OR, 1.97; 95% CI, 1.15‑3.37; P=0.013) and 2.35-fold increased risk for AF recurrence (RR, 2.35; 95% CI, 1.10-5.04; P=0.028) compared with the ACE gene II+ID genotype. However, no correlation between the CYP11B2 gene -344T/C polymorphism and lone AF or its recurrence was observed in this cohort. In conclusion, the ACE gene DD genotype was associated with an increased incidence of lone AF and its recurrence following ablation, which was partly mediated by LAD.

View Figures

View References

1	Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ and Wolf PA: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 271:840–844. 1994. View Article : Google Scholar : PubMed/NCBI
2	Jiang J, Shen F, Fang W, Liu X and Yang YQ: Novel GATA4 mutations in lone atrial fibrillation. Int J Mol Med. 28:1025–1032. 2011.PubMed/NCBI
3	Fatini C, Sticchi E, Gensini F, Gori AM, Marcucci R, Lenti M, Michelucci A, Genuardi M, Abbate R and Gensini GF: Lone and secondary nonvalvular atrial fibrillation: role of a genetic susceptibility. Int J Cardiol. 120:59–65. 2007. View Article : Google Scholar : PubMed/NCBI
4	Yang YQ, Liu X, Zhang XL, Wang XH, Tan HW, Shi HF, Jiang WF and Fang WY: Novel connexin40 missense mutations in patients with familial atrial fibrillation. Europace. 12:1421–1427. 2010. View Article : Google Scholar : PubMed/NCBI
5	Yang Y, Xia M, Jin Q, Bendahhou S, Shi J, Chen Y, Liang B, Lin J, Liu Y, Liu B, et al: Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am J Hum Genet. 75:899–905. 2004. View Article : Google Scholar : PubMed/NCBI
6	Belluzzi F, Sernesi L, Preti P, Salinaro F, Fonte ML and Perlini S: Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol. 53:24–29. 2009. View Article : Google Scholar : PubMed/NCBI
7	Tayebjee MH, Creta A, Moder S, Hunter RJ, Earley MJ, Dhinoja MB and Schilling RJ: Impact of angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers on long-term outcome of catheter ablation for atrial fibrillation. Europace. 12:1537–1542. 2010. View Article : Google Scholar : PubMed/NCBI
8	Klemm HU, Heitzer T, Ruprecht U, Meinertz T and Ventura R: Impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the long-term outcome after pulmonary vein isolation for paroxysmal atrial fibrillation. Cardiology. 117:14–20. 2010. View Article : Google Scholar
9	Marchesi C, Paradis P and Schiffrin EL: Role of the reninangiotensin system in vascular inflammation. Trends Pharmacol Sci. 29:367–374. 2008. View Article : Google Scholar : PubMed/NCBI
10	Rahman ST, Lauten WB, Khan QA, Navalkar S, Parthasarathy S and Khan BV: Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). Am J Cardiol. 89:686–690. 2002. View Article : Google Scholar
11	Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K and Saku K: Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 41:2197–2204. 2003. View Article : Google Scholar : PubMed/NCBI
12	Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M and Arakawa K: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 101:2612–2617. 2000. View Article : Google Scholar : PubMed/NCBI
13	Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA and Schunkert H: Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation. 92:1387–1388. 1995. View Article : Google Scholar : PubMed/NCBI
14	Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P and Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 86:1343–1346. 1990. View Article : Google Scholar : PubMed/NCBI
15	Watanabe H, Kaiser DW, Makino S, MacRae CA, Ellinor PT, Wasserman BS, Kannankeril PJ, Donahue BS, Roden DM and Darbar D: ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling. Heart Rhythm. 6:1327–1332. 2009. View Article : Google Scholar
16	White PC and Slutsker L: Haplotype analysis of CYP11B2. Endocr Res. 21:437–442. 1995. View Article : Google Scholar : PubMed/NCBI
17	Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, Jeunemaitre X, Corvol P, Pascoe L and Soubrier F: Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension. 32:198–204. 1998. View Article : Google Scholar : PubMed/NCBI
18	Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC and Klein HU: Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol. 88:906–909. 2001. View Article : Google Scholar : PubMed/NCBI
19	Amir O, Amir RE, Paz H, Mor R, Sagiv M and Lewis BS: Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. Am J Cardiol. 102:326–329. 2008. View Article : Google Scholar : PubMed/NCBI
20	Husser D, Adams V, Piorkowski C, Hindricks G and Bollmann A: Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol. 55:747–753. 2010. View Article : Google Scholar : PubMed/NCBI
21	Wang X, Liu X, Shi H, Tan H, Jiang W, Wang Y, Yang G and Zhou L: Early recurrences after paroxysmal atrial fibrillation ablation: when is the proper timing for reablation? Pacing Clin Electrophysiol. 34:709–716. 2011. View Article : Google Scholar : PubMed/NCBI
22	Liu X, Tan H, Wang X, Shi H, Li Y, Li F, Zhou L and Gu J: Efficacy of catheter ablation and surgical CryoMaze procedure in patients with long-lasting persistent atrial fibrillation and rheumatic heart disease: a randomized trial. Eur Heart J. 31:2633–2641. 2010. View Article : Google Scholar
23	Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, et al: Recommendations for chamber quantification. Eur J Echocardiogr. 7:79–108. 2006. View Article : Google Scholar : PubMed/NCBI
24	Ravn LS, Benn M, Nordestgaard BG, Sethi AA, Agerholm-Larsen B, Jensen GB and Tybjaerg-Hansen A: Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population. Pharmacogenet Genomics. 18:525–533. 2008. View Article : Google Scholar : PubMed/NCBI
25	Roux JF, Zado E, Callans DJ, Garcia F, Lin D, Marchlinski FE, Bala R, Dixit S, Riley M, Russo AM, et al: Antiarrhythmics after ablation of atrial fibrillation (5A study). Circulation. 120:1036–1040. 2009. View Article : Google Scholar : PubMed/NCBI
26	Balk EM, Garlitski AC, Alsheikh-Ali AA, Terasawa T, Chung M and Ip S: Predictors of atrial fibrillation recurrence after radio-frequency catheter ablation: a systematic review. J Cardiovasc Electrophysiol. 21:1208–1216. 2010. View Article : Google Scholar : PubMed/NCBI
27	Fogari R, Derosa G, Ferrari I, Corradi L, Zoppi A, Lazzari P, Santoro T, Preti P and Mugellini A: Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens. 21:1034–1039. 2008. View Article : Google Scholar : PubMed/NCBI
28	Staszewsky L, Wong M, Masson S, Raimondi E, Gramenzi S, Proietti G, Bicego D, Emanuelli C, Pulitanò G, Taddei F, et al: Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echo-cardiographic substudy. Circ Cardiovasc Imaging. 4:721–728. 2011. View Article : Google Scholar : PubMed/NCBI
29	Shin SH, Park MY, Oh WJ, Hong SJ, Pak HN, Song WH, Lim DS, Kim YH and Shim WJ: Left atrial volume is a predictor of atrial fibrillation recurrence after catheter ablation. J Am Soc Echocardiogr. 21:697–702. 2008.PubMed/NCBI
30	Arriagada G, Berruezo A, Mont L, Tamborero D, Molina I, Coll-Vinent B, Vidal B, Sitges M, Berne P and Brugada J; GIRAFA (Grup Integrat de Recerca en Fibril.lació Auricular) Investigators: Predictors of arrhythmia recurrence in patients with lone atrial fibrillation. Europace. 10:9–14. 2008. View Article : Google Scholar : PubMed/NCBI
31	Brasier AR, Recinos A III and Eledrisi MS: Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 22:1257–1266. 2002. View Article : Google Scholar : PubMed/NCBI
32	Huang M, Gai X, Yang X, Hou J, Lan X, Zheng W, Chen F and He J: Functional polymorphisms in ACE and CYP11B2 genes and atrial fibrillation in patients with hypertensive heart disease. Clin Chem Lab Med. 47:32–37. 2009. View Article : Google Scholar : PubMed/NCBI
33	Barbato A, Russo P, Siani A, Folkerd EJ, Miller MA, Venezia A, Grimaldi C, Strazzullo P and Cappuccio FP: Aldosterone synthase gene (CYP11B2) C−344T polymorphism, plasma aldosterone, renin activity and blood pressure in a multi-ethnic population. J Hypertens. 22:1895–1901. 2004.